Mar 09, 2020
D'Amore Healthcare Offers Ketamine Therapy
Oct 03, 2019
Pacific Ketamine Institute Introduces SPRAVATO(TM) Treatment for Depression and Mental Disorders
Oct 02, 2019
Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Aug 20, 2019
The Ketamine Healing Clinic of Los Angeles's Dr. David Mahjoubi is Featured in the Mic.com Article, "How Does Ketamine Treat Depression, and is it Safe?"
Jun 11, 2019
Actify Neurotherapies Announces Launch of SPRAVATO(TM) Pilot Program
Jun 06, 2019
Pacific Ketamine Institute Launches in Beverly Hills
May 30, 2019
NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression
May 21, 2019
New Data Highlights the Value of SPRAVATO(TM) (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
May 21, 2019
First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA
Mar 05, 2019
Houston based depression psychiatrist, Dr. Sandhya Prashad, M.D., tells how this new drug might save lives and cost less than expected
Mar 05, 2019
Janssen Announces U.S. FDA Approval of SPRAVATO(TM) (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
Mar 05, 2019
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic
Feb 14, 2019
Brain & Behavior Research Foundation Applauds FDA Expert Panel Decision to Recommend Approval of New Depression Treatment
Jan 03, 2019
New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Action
Sep 27, 2018
The VA Recognizes Ketamine As An Emergency Treatment For PTSD And Depression Patients At High Suicide Risk
Sep 21, 2018
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Sep 18, 2018
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Sep 04, 2018
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
May 31, 2018
Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression
May 05, 2018
New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression